A HEALTH ECONOMIC EVALUATION OF ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
CHOLESTEROL ATTAINMENT IN DYSLIPIDAEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
NURSING HOME RESIDENTS WITH STROKE
EVALUATION OF SURVIVAL AND ISCHAEMIC AND THROMBOEMBOLIC EVENT RATES IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN THE GENERAL POPULATION WHEN TREATED AND UNTREATED WITH WARFARIN
IMPACT OF RECENT RITONOVIR RE-PRICING ON COST-EFFECTIVENESS ANALYSIS
IS PROVISION OF ANTI-VIRAL INFLUENZA TREATMENT A SOUND INVESTMENT FOR PRIVATE AND PUBLIC EMPLOYERS IN THE UK?
ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN GREECE
POPULATION-BASED EVALUATION OF FUTURE BURDEN OF DISEASE AND COSTS RELATED TO CHRONIC HEPATITIS C AND ANTIVIRAL TREATMENT STRATEGIES
COMPLIANCE,ADHERENCE,AND PERSISTENCE
CORRECTING FOR COMPENSATING MECHANISMS RELATED TO PRODUCTIVITY COSTS IN ECONOMIC EVALUATIONS OF HEALTH CARE PROGRAMS
QALYS LACK QUALITY IN PAEDIATRIC CARE
FLEXIBILITY AND TRANSPARENCY OF BAYESIAN NETWORKS
AGREEMENT BETWEEN PATIENTS' AND CLINICIANS'-REPORTED OUTCOMES IN LIPODYSTROPHY (HIV/AIDS)
THE HEALTH RELATED QUALITY OF LIFE IN PARKINSON'S DISEASE IN GERMANY
QUALITY OF LIFE OF GASTROESOPHAGEL REFLUX DISEASE PATIENTS
PATIENT-RATED UTILITIES IN POSTMENOPAUSAL EARLY BREAST CANCER (EBC)
THE COSTS AND EFFECTS OF CLOPIDOGREL IN COMPARISON TO ASA OR PLACEBO FOR SEVERAL PATIENT POPULATIONS IN DENMARK
WHAT IS THE ADDED VALUE OF HEALTH RELATED QUALITY OF LIFE (HRQL) DATA? AN EXAMPLE FROM THE INTERNATIONAL SUBARACHNOID ANEURYSM TRIAL (ISAT)
MODELLING SURVIVAL AND COSTS IN SWITZERLAND OF NESIRITIDE VERSUS INOTROPIC THERAPY FOR ACUTE DECOMPENSATED HEART FAILURE
PHARMACOECONOMIC CONSEQUENCES OF PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLIC
TRENDS IN OUTCOMES AND COSTS FOR U.S. PATIENTS WITH ADVANCED NON-SMALL LUNG CANCER 1994–2001
COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB + CHOP VERSUS CHOP IN PATIENTS WITH AGGRESSIVE NON-HODGKIN LYMPHOMA
COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-α) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS
COST-EFFECTIVENESS OF SAMARIUM-153-EDTMP COMPARED TO CONVENTIONAL PAIN THERAPY IN GERMANY
ANNUAL BURDEN OF DRY EYE SYNDROME IN SIX EUROPEAN COUNTRIES
PRODISQ A MODULAR QUESTIONNAIRE ON PRODUCTIVITY AND DISEASE FOR ECONOMIC EVALUATION STUDIES IN PATIENT SETTINGS AND ORGANISATIONAL SETTINGS
USING STATED RISK-BENEFIT TRADEOFF PREFERENCES TO IDENTIFY POTENTIAL THERAPEUTIC RISK-MANAGEMENT PROBLEMS
COMPARING THE INTERVAL PROPERTIES OF HEALTH-STATE VALUATIONS MEASURED USING THE VISUAL ANALOGUE SCALE AND RANK-BASED SCALING
VALIDATION OF THE GERMAN PROSTATE SPECIFIC MODULE (PSM)
THE BARTHEL PREFERENCE INDEX (BPI)
VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE THE SEVERITY OF LOWER URINARY TRACT SYMPTOMS IN UNCOMPLICATED URINARY TRACT INFECTION
DEVELOPMENT AND VALIDATION OF THE DIAPASON
INCREMENTAL COST-EFFECTIVENESS OF THREE CLASSES OF ANTI-DEPRESSANTS
MODELING ANTIPSYCHOTICS MARKET SHARE EVOLUTION TREATMENT
SCHIZOPHRENIA AND QUALITY OF LIFE ASSESSMENTS
ADHD-RELATED PATIENT AND FAMILY BURDEN
ASSOCIATION BETWEEN ANTIPSYCHOTIC DRUGS AND DIABETES MELLITUS
LABOR MARKET EFFECTS OF INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES AMONG CANADIAN LABOR FORCE
DECREASED RATES OF MAJOR HYPOGLYCAEMIC EVENTS LEAD TO IMPROVED LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS BIPHASIC HUMAN INSULIN 30 IN TYPE 2 DIABETIC SUBJECTS IN DANISH, FINNISH, GERMAN, NORWEGIAN, SPANISH, SWEDISH,AND UK SETTINGS
PROOF OF CONCEPT OF A WIRELESS APPROACH FOR ENABLING COMMUNICATIONS BETWEEN GERMAN PHYSICIANS AND THEIR PATIENTS WITH TYPE 2 DIABETES TREATED WITH NATEGLINIDE
HEALTH ECONOMIC COMPARISON OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION WITH MULTIPLE DAILY INJECTION FOR THE TREATMENT OF TYPE 1 DIABETES IN THE UK
PATIENTS' PREFERENCES FOR INGUINAL HERNIA REPAIR
A FIVE-LEVEL VERSION OF EQ-5D
VARIATION IN ADL FUNCTIONING WITHIN BARTHEL INDEX SCORES
THE RELATIONSHIP BETWEEN HEALTH INSURANCE TYPE AND COSTS OF PRESCRIBED DRUGS
EVALUATION OF CONDITIONAL REIMBURSEMENT AS A POLICY-INSTRUMENT
PHARMACOECONOMIC EDUCATION AT NON-US COLLEGES OF PHARMACY
DRUG COSTS DEVELOPMENT AFTER PATENT EXPIRY IN THE THE NETHERLANDS
HEALTH-RELATED QUALITY OF LIFE IN NEUROMUSCULAR DISEASES
COST ASSOCIATED WITH PERSISTENCY AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER SWITCHING TO OXCARBAZEPINE MONOTHERAPY
A COST-UTILITY MODEL OF TREATMENT OF NEWLY DIAGNOSED EPILEPSY IN GERMANY COMPARING TOPIRAMATE, CARBAMAZEPINE AND VALPROATE
12-MONTHS COSTS OF PARKINSON'S DISEASE IN GERMANY—RESULTS OF A PROSPECTIVE STUDY
SUNBURNS ACCORDING TO GENDER
LIVING WITH A DERMATOSIS
COST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS
COMPARING TREATMENT COSTS ASSOCIATED WITH SCREENING FOR GLAUCOMA VS NOT SCREENING
TEGASEROD IS COST-EFFECTIVE IN THE TREATMENT OF PATIENTS WITH IBS
COST-EFFECTIVENESS OF COMPETING ANTIPSYCHOTIC MONOTHERAPIES IN ACUTE BIPOLAR MANIA IN THE U.K.
IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING COMPARED TO STANDARD BLOOD PRESSURE CONTROL ALONE FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION,AND MICROALBUMINURIA IN SPANISH, SWEDISH AND SWISS SETTINGS
ANTIPSYCHOTIC PATTERNS AND TREATMENT COST IN FRANCE
WHAT HAPPENS WHEN A PHARMACEUTICAL PRODUCT IS REMOVED OUT OF REIMBURSEMENT?
MODELLING USE OF HOSPITAL SERVICES AS A FUNCTION OF NEEDS AND SUPPLY IN ITALY
STRATEGIES OF PRIORIZATION BASED ON THE SOCIAL WELFARE FUNCTION
EXPLAINING THE LACK OF SUCCESS OF GENERIC DRUGS IN BELGIUM
LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS
PUBLIC HEATH SYSTEM EXPENSES ON CHILDREN'S ATOPIC DERMATITIS TREATMENT IN VLADIVOSTOK CITY
RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF SEVERITY IN FIVE EUROPEAN COUNTRIES
A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF SALMETEROL AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF FLUTICASONE AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
IMPACT OF A DISEASE MANAGEMENT PROGRAM ON CONTROL OF ASTHMA IN NORMANDY
A COMPARISON OF TWO APPROACHES TO ESTIMATE ANNUAL MEDICATION COSTS IN THE KORA ASTHMA AND ALLERGY STUDY
COST ESTIMATION IN CLINICAL PIGGY-BACK STUDIES WITH DISCONTINUATIONS—COMPARISON OF DIFFERENT APPROACHES
FROM SF-36 TO UTILITY SCORES
HE BURDEN OF ANKYLOSING SPONDYLITIS IN AUSTRALIA
THE TOTAL COST OF TREATMENT AND THE COST-EFFECTIVENESS OF VALDECOXIB VS DICLOFENAC IN THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS (OA) OF THE HIP AND/OR KNEE
QUANTIFYING DISEASE SEVERITY AS A DETERMINANT OF COSTS AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN AUSTRALIA
THE COART STUDY
MESSAGE
ECONOMIC EVALUATION OF THERAPY WITH NSAID AND WITH COX-2 IN SUBJECTS AGED 66 YEARS OR MORE
FIBROMYALGIA COST OF CARE
HEALTH ECONOMIC EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB
A COST MINIMISATION ANALYSE FOR STUDYING THE EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING
PATTERNS OF DOSING WITH ADALIMUMAB AMONG COMMERCIALLY INSURED PATIENTS
A COST EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS
HOW ADEQUATE DO RA-PATIENTS REPORT INDIRECT COSTS?—THE EXAMPLE OF A GERMAN COHORT
COST-EFFECTIVENESS OF VALDECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN THE UK (UK) AND GERMANY
COSTS OF RA IN GERMANY ON A MICRO-COSTING LEVEL
A COMPARISON OF COST OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY
CO-PAYMENTS IN RHEUMATOID ARTHRITIS OBSERVED IN A GERMAN COHORT
LINGUISTIC ADAPTATION AND VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS) INTO SPANISH
ASSESSMENT OF HEALTH STATUS IN A NATIONAL SAMPLE OF U.S. OSTEOARTHRITIC PATIENTS
ASSESMENT OF QUALITY OF LIFE (QOL) IN ADULTS WITH JUVENILE IDIOPATIC ARTHRITIS (AIJ) DIAGNOSIS IN MEXICO
SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH RHEUMATOLOGISTS IN 2003
PEOPLES PREFERENCES FOR WHO SHOULD GET THE NEXT JOINT REPLACEMENT
CROSS-SURVEY OF RHEUMATOLOGISTS AND GP AWARENESS AND KNOWLEDGE OF FIBROMYALGIA
FIBROMYALGIA SYNDROM
SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH GENERAL PRACTITIONERS
RELATIONSHIPS BETWEEN AGE, NUMBER OF PRESCRIPTIONS, AND CO-MORBIDITIES AMONG VA PATIENTS
CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED TO PREDICT FUTURE RISK OF NSAID-INDUCED GASTROINTESTINAL EVENTS
COST-UTILITY OUTCOMES SIMULATION MODEL FOR OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA) PATIENTS (COSMO)
ASSESSING INTANGIBLES IN BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS (RA). A WILLINGNESS TO PAY (WTP) STUDY IN SPANISH PATIENTS
COST-EFFECTIVENESS OF APREPITANT GIVEN WITH STANDARD ANTIEMETICS IN PATIENTS RECEIVING CHEMOTHERAPY IN OFFICE-BASED SETTINGS IN GERMANY
COST-EFFECTIVENESS OF IMATINIB (GLEEVEC) AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
COST-EFFECTIVENESS OF BORTEZOMIB (VELCADE) FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER
COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC)
HOSPITALIZATION COSTS OF PATIENTS WITH INFECTIONS WHO HAVE LUNG CANCER OR NEUTROPENIA IN SWEDEN—A RETROSPECTIVE DATABASE STUDY
THE LIFETIME COST OF GEFITINIB (“IRESSA”) IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)
COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK
A TIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK
COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)
COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCER WITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK
COST EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER
COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-GEMCYTABINE
ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)
GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2)
COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY
DOES GEMCITABINE PLUS CISPLATIN PROVIDE VALUE FOR MONEY IN THE TREATMENT OF ADVANCED NON-SMALLCELL LUNG CANCER IN THE UK?
A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY
NEW TARGETED THERAPY FOR PATIENTS WITH PREVIOUSLY-TREATED ADVANCED NON-SMALL CELL LUNG CANCER—GEFITINIB (“IRESSA”)
COSTS OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER IN SPAIN USING GEMCITABINE IN COMBINATION WITH CISPLATIN
A PHARMACOECONOMIC MODEL OF THE COSTEFFECTIVENESS OF GEFITINIB (“IRESSA”) COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALLCELL LUNG CANCER (NSCLC) IN THE UK
A SYSTEMATIC EVALUATION OF THE IMPACT OF THE SCREENING INTERVAL ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER SCREENING TECHNIQUES
A COST MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIAL (GREAT) IN THE TREATMENT OF NONSMALL-CELL LUNG CANCER IN TAIWAN
COST-EFFECTIVENESS-ANALYSIS OF THE THERAPY OF STAGE T1–T2 PROSTATE CANCER WITH PERMANENT SEED IMPLANTATION IN COMPARISON WITH RADICAL PROSTATECTOMY
PCN26
PATIENT PREFERENCE FOR ANASTROZOLE AS ADJUVANT HORMONAL THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY
QUALITY OF LIFE AND SEXUALITY IN PATIENTS WITH RECTAL CANCER
PROSTATE CANCER SPECIFIC SYMPTOMS IN A GERMAN REFERENCE POPULATION
IMPROVED TOXICITY PROFILE OF PEMETREXED VS DOCETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS TRANSLATES TO COST SAVINGS IN SPAIN
EVALUATION OF PEMETREXED VERSUS DOCETAXEL IN THE SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
INSTRUMENTS TO MEASURE PATIENT-REPORTED OUTCOMES AND PERCEPTIONS OF CANCER-RELATED FATIGUE
HEALTH UTILITY VALUES FOR CANCER RELATED ANAEMIA
UTILITY ASSOCIATED WITH SEVERITY OF CANCER-RELATED ANAEMIA (CRA)
VALUATION OF SOCIETAL PREFERENCE BETWEEN THERAPIES FOR CANCER-RELATED ANAEMIA (CRA)
THE VALUE OF THE USE OF ANASTROZOLE AS AN ALTERNATIVE ADJUVANT THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TOPAY (WTP) METHODOLOGY
DIFFERENCES IN TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS
THE IMPACT OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY—A DECISION ANALYSIS
QUALITY ASSURANCE IN CANCER CHEMOTHERAPY THROUGH PHARMACEUTICAL CARE DOCUMENTATION
DISPARITIES IN MEDICAID CANCER EXPENDITURES
ASSESSMENT OF DIFFERENT STRATEGIES FOR DETERMINING DIAGNOSIS AND RESECTABILITY IN PATIENTS WITH SUSPECTED PANCREATIC CANCER
POOLING CLINICAL AND COST OUTCOMES
MAPPING HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENTS INTO GENERIC UTILITY MEASURES (EQ-5D)
META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR COLORECTAL CANCER
MODELING EFFECT IN PHARMACOECONOMICS ANALYSIS USING ARTIFICIAL NEURAL NETWORKS
DRUG USE PROFILES AFTER HOSPITALIZATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE NETHERLANDS AND THE RISK ON REHOSPITALIZATION
ITEM SELECTION FOR COPD-SPECIFIC UTILITY INSTRUMENT
DEVELOPMENT OF A COPD SEVERITY SCORE IN CLAIMS DATABASE
THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN TAIWAN
ACHIEVEMENT OF THE EUROPEAN 1998 LDL-C GOAL BY HYPERCHOLESTEROLAEMIC PATIENTS IN THE STELLAR TRIAL
TIME TO LDL-CHOLESTEROL GOAL ATTAINMENT IN SPAIN
FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION
THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN CHINA
LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL® IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION IN GERMANY
AN ECONOMIC EVALUATION OF CLOPIDOGREL VS. ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISK ATHEROTHROMBOTIC PATIENTS IN ITALY
THE COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN POLAND
THE ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
COST-EFFECTIVENESS ANALYSIS OF ALTEPLASE COMPARED WITH STREPTOKINASE AND ABSENCE OF THROMBOLYTICAL THERAPY FOR MYOCARDIAL INFARCTION
THE COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN
COST EFFECTIVENESS OF ADDING NIASPAN TO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
SECONDARY PREVENTION AFTER PCI
ECONOMIC ASSESSMENT OF EZETIMIBE COADMINISTRATION IN A HUNGARIAN CHD PATIENT COHORT NOT AT CHOLESTEROL GOAL ON SIMVASTATIN MONOTHERAPY
AN ECONOMIC ANALYSIS OF CATHETER ABLATION FOR THE TREATMENT OF VENTRICULAR TACHYCARDIA
COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN
EVOLUTION OF PRESCRIPTIONS AND DRUG COSTS IN HYPERTENSION—RESULTS FROM A DATABASE FOLLOW-UP STUDY
COSTS OF HYPERTENSION IN POLAND MEASURED FROM THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON WITH THE SOCIETAL PERSPECTIVE
COSTS OF HYPERTENSION IN THE ELDERLY IN COMPARISON WITH PATIENTS UNDER 65 IN POLAND
COST-EFFECTIVENESS ANALYSIS OF THE MANAGEMENT OF ARTERIAL HYPERTENSION
COST EFFECTIVENESS OF ANTIHYPERTENSIVE MONOTHERAPY WITH PERINDOPRIL OR ENALAPRIL IN ELDERLY PATIENTS FROM THE THIRD PARTY PAYER PERSPECTIVE
ECONOMIC EVALUATION OF VARIOUS ANTIHYPERTENSIVE MONOTHERAPIES IN GREECE
THE COST EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT) FOR WOMEN WITH MENOPASUAL SYMPTOMS IN SWEDEN
ACUTE COSTS OF STROKE IN THE UK NATIONAL HEALTH SERVICE IN 2002–2004
PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL
SMOKING CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY
COST-EFFECTIVENESS OF BUPROPION IN SMOKING CESSATION IN FINLAND
COST-EFFECTIVENESS OF RAMIPRIL IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS
COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS, TREATED FOR HYPERTENSION
COST-EFFECTIVENESS OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN THE DIAGNOSTIC ASSESSMENT AND MANAGEMENT OF PATIENTS WITH DYSPNEA IN THE EMERGENCY DEPARTMENT
COST OF IN-PATIENT CARE AFTER ADMISSION FOR WARFARIN ASSOCIATED ADVERSE DRUG REACTIONS
SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS® 1442—A PROSPECTIVE 3-YEAR PHARMACOECONOMIC STUDY
MODELING THE ECONOMIC IMPACT OF NEW IMPLANTABLE DEFIBRILLATORS WITH A LONGER LIFETIME
COST-EFFECTIVENESS OF ANTICOAGULATION WITH BIVALIRUDIN VS. HEPARIN AND GLYCOPROTEIN INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN
ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FOR A COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN MONOTHERAPY
ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN ITALY
ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY
COSTS OF MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION
MODELING THE ECONOMIC CONSEQUENCES OF IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER PACEMAKERS IN THE UK
COSTS OF ISCHEMIC STROKE TREATMENT IN RUSSIAN FEDERATION
COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF HYPERCHOLESTEROLEMIA IN CATALONIA, SPAIN
PUBLIC HEALTH AND ECONOMIC IMPACTS OF RAISING THE LEGAL SMOKING AGE IN CALIFORNIA
THE IMPACT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN USAGE ON OUTCOMES OF TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS) IN RUSSIA
VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION
A SHORT-TERM RETROSPECTIVE ECONOMIC EVALUATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION WITH ANGIOTENSIN II-ANTAGONISTS IN SPAIN
SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN MEN. AN ECONOMIC EVALUATION BASED ON A SYSTEMATIC REVIEW OF THE LITERATURE
DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE
ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER—IMPACT ON COST OF THERAPY
CHRONIC VENOUS DISEASE AND DEPRESSIVE SYMPTOMATOLOGY
CHRONIC VENOUS DISEASE
CHRONIC VENOUS DISEASE AND HEALTH STATUS
VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) QUESTIONNAIRE
TRENDS IN PREVALENCE,AWARENESS,TREATMENT,AND CONTROL OF HYPERTENSION AMONG CHINESE AMERICANS FROM 2001 THROUGH 2004
USE OF VISUAL ANALOGUE SCALE (VAS) AS A METHOD OF DISCRIMINATION FOR PHYSICAL DISABILITY SEVERITY IN STROKE
DISEASE SPECIFIC VERSUS GENERIC OUTCOME ASSESSMENT IN PULMONARY HYPERTENSION
PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERCHOLESTEROLEMIA AMONG CHINESE AMERICANS
CHRONIC VENOUS DISEASE
CHRONIC VENOUS DISEASE
CHRONIC VENOUS DISEASE
TREATMENT OF NEWLY-DIAGNOSED HYPERTENSIVE PATIENTS IN ITALY
THE USE OF INTERNET-BASED TECHNOLOGY TO ASSESS MEDICATION ADHERENCE IN PATIENTS WITH HYPERTENSION AND TO PROVIDE INTERACTIVE HEALTH INFORMATION
HYPERTENSION CLINIC AND HYPERTENSION SPECIALIST IS A COST-EFFECTIVE TOOL FOR THE DISEASE CONTROL IMPROVEMENT IN BELARUS
OVER-ADHERENCE WITH ANTIHYPERTENSIVE MEDICATIONS AMONG CENTRAL TEXAS VETERANS
FACTORS ASSOCIATED WITH ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS IN CENTRAL TEXAS
PERSISTENCE WITH DIFFERENT FORMULATIONS OF THE ANTIHYPERTENSIVE DRUG NIFEDIPINE
POOLED EFFICACY OF DISEASE MANAGEMENT PROGRAMS IN PATIENTS WITH CONGESTIVE HEART FAILURE—A SYSTEMATIC REVIEW
USE OF CLOPIDOGREL AFTER ISCHEMIC VASCULAR EVENTS IN THE THE NETHERLANDS
POPULATION IMPACT OF LOSARTAN USE ON STROKE IN FRANCE
ATTITUDES OF OFFICE-BASED PHYSICIANS TOWARDS ANTI-COAGULATION TREATMENT
DECISION ANALYSIS AND COSTS OF LOW MOLECULAR WEIGHT HEPARINS
EFFECT OF STATIN TITRATING ON CHOLESTEROL REDUCTION AND GOAL ATTAINMENT IN ACTUAL CLINICAL PRACTICE IN GERMANY
CHOLESTEROL GOAL ATTAINMENT AMONG PATIENTS TREATED WITH LIPID LOWERING DRUGS IN HUNGARY
COSTS ASSOCIATED WITH ALTERNATIVE FETAL CARDIOLOGY REFERRAL MODES
A METHOD FOR IDENTIFYING PATIENTS WITH CHRONIC ANGINA FROM ADMINISTRATIVE CLAIMS DATA
THE APPLICATION OF TWO ANALYTIC METHODS TO INVESTIGATE THE INFLUENCE OF POOR INR CONTROL ON RISKS OF HOSPITALISATION FOR PATIENTS RECEIVING WARFARIN
USING A PATTERN MIXTURE MODEL TO UNDERSTAND THE IMPACT OF NON-RANDOM MISSING DATA IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOING NON-CARDIAC VASCULAR SURGERY
ASSESSING THE LIKELIHOOD OF FRACTURE WITH ORAL ANTI-SPASTICITY MEDICATIONS
RETAIL PRICES DECREASED 30% IN FINLAND IN 1994–2003 EVEN BEFORE INTRODUCTION OF GENERIC SUBSTITUTION
IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION
APPLICATION OF THE DELPHI TECHNIQUE IN THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR USE IN METHADONE MAINTENANCE PROGRAMS
PERSPECTIVE OF THE GENERIC MARKET IN FRANCE
DECISION MAKING IN ITALIAN HEALTH CARE
PRESCRIPTION PATTERN OF ALIMENTARY TRACT DRUGS AFTER CHANGES OF DRUG BENEFIT STATUS IN KOREA
THE IMPACT OF PHARMACEUTICAL MARKET COMPETITION ON PRICE AND REIMBURSEMENT STATUS OF PATENTED DRUGS IN THE NETHERLANDS, BELGIUM, FRANCE AND GERMANY
REIMBURSMENT POLICY IN TURKEY
ECONOMIC EVALUATION BETWEEN ALTERNATIVE PATTERNS OF OUTPATIENT CARE IN GREECE
PHP9
EMERGENCY DEPARTMENT VISITS FOR INJURIES RESULTING FROM BICYCLE ACCIDENTS
PRESCRIBING PATTERNS OF CIPROFLOXACIN AND LEVOFLOXACIN IN AN ITALIAN GERIATRIC HOSPITAL
COST VARIANCES IN G-DRG GROUPS. THE EXAMPLE OF RHBMP-2 IN SPINE FUSION SURGERY
THE HOSPITAL DIAGNOSTIC THERAPEUTIC PATHWAY OF PATIENTS AFFECTED BY CRITICAL ISCHEMIA OF THE LOWER LIMBS WHICH IS UNRESPONSIVE TO REVASCULARIZATION
ECONOMIC ASPECTS OF INDIVIDUAL TREATMENT IN POLAND—OUT–PATIENT VIEWPOINT
PREFERENCES MATTER
PHARMACOECONOMICS INTRODUCTION IN THE CREATION OF POSITIVE DRUG LIST IN BULGARIA
MEDICINAL CANNABIS IN THE NETHERLANDS
INTRODUCING THE ‘FOURTH HURDLE’ IN THE NEW EUROPEAN UNION MEMBER STATES
EFFECTS OF DEVOLUTION OF SUBSIDIES FOR PHARMACEUTICALS IN SWEDEN
PROPER DRUG MANAGEMENT IN PHARMACY—THE ROLE OF PHARMACOECONOMICS AS PERCEIVED BY POLISH PHARMACISTS
QUALITY ASSESSMENT OF AN AMBULATORY CARE CLINIC BASED COLLABORATIVE CARE APPROACH FOR ACHIEVING THERAPEUTIC GOALS
MEDICATION AND SOCIO-ECONOMIC STATUS IN A POPULATION-BASED COHORT STUDY
ANALYSIS OF CLINICAL INTERVENTION DOCUMENTATION BY PHARMACISTS
ANALYSIS OF “INNOVATOR” DRUGS FINANCED BY SPANISH NATIONAL HEALTH SERVICE OVER THE PERIOD 1996–2003
WILLINGNESS TO PAY VERSUS OUT OF POCKET PAYMENTS FOR HEALTH SERVICES UTILIZATION IN GREECE
PHYSICIANS'ACTIVITY HETEROGENEITY
AGE AND GENDER DISTRIBUTION OF PHARMACEUTICAL EXPENDITURE PER INHABITANT
THE ORGANIZED REGISTER OF CANADIAN HEALTH INFORMATION DATABASES (ORCHID) PROJECT
PATHOLOGY RELATED DIFFERENCES IN VARIANCE OF DRUG INSURANCE COST IN HOSPITAL STAYS
2006 DRUG PAYMENTS IN THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM
SENSIBLE FLEXIBILITY OR UNNECESSARY DUPLICATION? THE USE OF DECISION MODELLING IN NICE APPRAISALS
LOSS PROFILES DERIVED FROM ACTIVITY OF DAILY LIVING SCORES ATTRIBUTABLE TO HANDICAPS
SATISFACTION AMONG GERMAN PHYSICIANS—A REPRESENTATIVE EMPIRICAL STUDY
ENTERAL FEEDING IN THE COMMUNITY
RESOURCE USE AND COSTS OF PATIENTS RECEIVING ENTERAL NUTRITION IN PRIMARY AND SECONDARY CARE IN THE UK
THE INFLUENCE OF CHANGE OF CO-PAYMENT TO THE USE OF ANTIBIOTIC AGENTS
USE OF PATIENT-REPORTED OUTCOMES IN EVALUATION OF HEART FAILURE DEVICE THERAPY
SELF-EFFICACY AND ACADEMIC ACHIEVEMENT OF THE FIFTH YEAR PHARMACY STUDENTS OF CHULALONGKORN UNIVERSITY, 2003
OBESITY AND THE RISK OF UPPER RESPIRATORY TRACT INFECTIONS
SOCIAL COST OF OVERWEIGHT AND OBESITY
EVALUATION OF THE COST-UTILITY OF ORLISTAT (XENICAL) IN THE UNITED KINGDOM
EVALUATING THE IMPACT OF WEIGHT LOSS ON QUALITY OF LIFE IN PATIENTS TAKING ORLISTAT AND ENROLLED IN THE MOTIVATION,ADVICE AND PRO-ACTIVE SUPPORT (MAP) PROGRAMME
COST AND QUALITY OF LIFE IN OBESITY
COST-EFFECTIVENESS OF RISENDRONATE THERAPY COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN AT HIGH RISK OF OSTEOPOROTIC FRACTURE
CLINICAL AND ECONOMIC IMPACT OF RISEDRONATE TREATMENT FOR POST-MENOPAUSAL OSTEOPOROSIS IN FRANCE
TREATMENT COSTS AND DISEASE BURDEN OF PATIENTS WITH PAGET'S DISEASE
COST-EFFECTIVENESS OF BONE STIMULATORS IN THE CONSERVATIVE TREATMENT OF STABLE NONUNION FRACTURES
MEDICO-ECONOMIC EVALUATION OF VERTEBRAL FRACTURE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
COST-EFFECTIVENESS OF MIACALCIC IN TREATMENT OF PAIN DUE TO OSTEOPOROTIC VERTEBRAL FRACTURE
PERSISTENCE AND COMPLIANCE WITH BISPHOSPHONATE THERAPY AMONG POST-MENOPAUSAL OSTEOPOROTIC WOMEN
PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS
EPIDEMIOLOGY OF OSTEOPOROSIS IN THE NETHERLANDS (1993–2002)
THE UNDER TREATMENT OF DEPRESSION IN CHRONIC PAIN
ESTIMATING THE INCIDENCE AND COSTS OF TREATING ADVERSE EVENTS IN PATIENTS TREATED WITH STRONG OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN
RESOURCE UTILISATION OF PATIENTS WITH CHRONIC PAIN CONDITIONS BEFORE AND DURING TREATMENT WITH LONG-ACTING OPIOIDS IN GERMANY
AN OBSERVATIONAL STUDY OF INTRAVENOUS PATIENTCONTROLLED ANALGESIA RESOURCE UTILIZATION AT AN ACADEMIC MEDICAL CENTER
COST-EFFECTIVENESS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL IN TREATMENT OF SUBACUTE LOW BACK PAIN IN A DUTCH HEALTH CARE SETTING
PROSPECTIVE ASSESSMENT OF THE HEALTH AND ECONOMIC BURDEN OF NEUROPATHIC PAIN
BURDEN OF ILLNESS SURVEY IN PATIENTS WITH PAINFUL NEUROPATHIC DISORDER (PNDS) IN GERMANY
USE OF THE NEUROPATHIC PAIN SCALE IN AN INTERNATIONAL STUDY
RESPONSIVENESS OF THE SHUTTLE WALKING TEST COMPARED WITH DISEASE SPECIFIC AND GENERIC OUTCOME MEASURES IN PATIENTS WITH CHRONIC BACK PAIN
AGREEMENT BETWEEN PATIENTS' AND CLINICIANS'REPORTED OUTCOMES IN 3 CHRONIC DISEASES
QUANTIFICATION OF SUSPECTED ADDICTION TREATMENT OF NARCOTIC ANALGESICS USING PRESCRIPTION SEQUENCE ANALYSIS
DEVELOPMENT OF AN INSTRUMENT TO CAPTURE EASE-OFCARE OUTCOMES IN PATIENTS TREATED WITH PCA DELIVERY SYSTEMS
DEVELOPMENT OF TWO INSTRUMENTS TO CAPTURE EASE-OF-CARE OUTCOMES IN HEALTH-CARE PROVIDERS WHO CARE FOR PATIENTS TREATED WITH PCA DELIVERY SYSTEMS
EVALUATION OF MONOTHERAPY AND COMBINATION ANTIBIOTIC TREATMENT REGIMENS FOR PSEUDOMONAS AERUGINOSA PNEUMONIA
COST OF CHRONIC BRONCHITIS (CB) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN FRANCE
PHARMACOECONOMY AND ANTIBIOTIC TREATMENT WITHIN THE SLOVAK REPUBLIC
COST OF TREATMENT AND REIMBURSEMENT OF HOSPITALIZED COMMUNITY-ACQUIRED PNEUMONIA WITH I.V. MOXIFLOXACIN COMPARED TO STANDARD ANTIBIOTIC TREAMENT IN GERMANY
COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITAL'S PERSPECTIVE IN GERMANY—FINAL RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY
A CANADIAN COST ANALYSIS OF 4 RANDOMIZED DOUBLEBLIND ACTIVE COMPARATOR TRIALS WITH TELITHROMYCIN IN ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) AND COMMUNITY-ACQUIRED PNEUMONIA (CAP)
THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE HAS A NEGATIVE IMPACT ON THE QUALITY OF LIFE OF THE PATIENT
IMPACT ON USE AND COST OF MEDICINES OF EXPANDED DRUG COVERAGE VIA POSITIVE LIST IN THE PHILIPPINES
COST OF KALIUM SUPPLEMENTATION WITH KALIPOZ PROLONGATUM OR KALDYUM FROM PAYER PERSPECTIVE IN POLAND
ECONOMIC IMPACT OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM) IN PATIENTS WITH HEMOPHILIA A
ECONOMIC MODELING OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHFPFM)
COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN JAPAN
COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH FONDAPARINUX IN MAJOR ORTHOPAEDIC SURGERY IN SWITZERLAND
ISAM
PBR7
PHYSICIANS' AND PHARMACISTS' PREFERENCES FOR HEMOPHILIA TREATMENT EVALUATED BY CONJOINT ANALYSIS
ASSESSING HEALTH-RELATED QUALITY OF LIFE IN ROMANIAN HAEMOPHILIACS
ESTABLISHING HEMOPHILIA PATIENTS' PREFERENCES IN PROPHYLAXIS
QUALITY OF LIFE IS ASSOCIATED TO ORTHOPEDIC STATUS IN HEMOPHILIACS WITH INHIBITORS
CLINICAL AND SOCIO-DEMOGRAPHIC CHARACTERISTICS INFLUENCE PATIENTS' PREFERENCES TOWARDS HEMOPHILIA TREATMENT
ASSOCIATION OF PATIENTS' KNOWLEDGE AND ADHERENCE TO MEDICAL ADVICE TO GLYCAEMIC CONTROL IN THE MANAGEMENT OF DIABETES MELLITUS
EVALUATION OF IMPROVED UTILITY ESTIMATES IN COST EFFECTIVENESS ANALYSIS OF MULTIPLE COMPLICATIONS IN TYPE-2 DIABETES
COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UNITED KINGDOM
THE DIABETES TYPE-2 COST PREDICTORS
COMMUNITY EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS IN GERMANY
THE COST OF TYPE-2 DIABETES IN UKRAINE
LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN GLARGINE IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES POORLY CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH, SWEDISH AND UK SETTINGS
WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?
THE VALUE OF ORAL MONOTHERAPY ALTERNATIVES IN THE FIRST-LINE TREATMENT OF TYPE-2 DIABETES MELLITUS
THE COST-EFFECTIVENESS OF PIOGLITAZONE IN COMBINATION WITH METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SCOTLAND
PHARMACOECONOMIC ASPECTS OF USE OF INSULIN GLARGINE IN TREATMENT OF DIABETES MELLITUS TYPE 2 (DM T2) IN RUSSIA
COSTS OF TYPE-2 DIABETES MELLITUS
ECONOMIC EVALUATION OF THE STEPPED VERSUS ORDINARY CARE FOR PREVENTION OF TYPE-2 DIABETES IN THE JDPP
COST-EFFECTIVENESS OF MONO-AND COMBINATION THERAPY WITH PIOGLITAZONE COMPARED TO GLICLAZIDE IN PATIENTS WITH TYPE-2-DIABETES MELLITUS FROM A GERMAN STATUTORY HEALTH CARE PERSPECTIVE
A COST-EFFECTIVENESS ANALYSIS OF SWITCHING TYPE-2 DIABETES PATIENTS FROM IMMEDIATE-RELEASE METFORMIN (GLUCOPHAGE®) TO A NEW EXTENDEDRELEASE FORMULATION OF METFORMIN (GLUCOPHAGE®XR)
EFFECT OF PATIENT EDUCATION IN TYPE-2 DIABETES OVER 10 YEARS BASED ON A PROSPECTIVE DIABETES MODEL IN THE PROVINCE OF STYRIA,AUSTRIA
ABSOLUTE AND INCREMENTAL EFFECTS OF THERAPYSWITCHING THRESHOLDS ON THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESE TYPE-2 DIABETES PATIENTS IN GERMANY
SEARCHING FOR DIABETES MELLITUS (DM) IN PRIMARY CARE—IT IS GOOD VALUE-FOR-MONEY IN POLAND? (COST OF DIAGNOSING DIABETES MELLITUS IN PRIMARY CARE CONDITION IN POLAND)
COST OF HOSPITAL ADMISSIONS FOR CARDIOVASCULAR DISEASE OVER FIVE YEARS IN PATIENTS WITH DIABETES MELLITUS
COST AND OUTCOMES OF THE DIABETES CLINIC IN A COMMUNITY HOSPITAL, MAE HONG SON,THAILAND
ECONOMIC VALUE OF ACARBOSE TREATMENT IN PERSONS WITH IMPAIRED GLUCOSE TOLERANCE (IGT) FOR THE GERMAN HEALTH CARE SYSTEM
COST-EFFECTIVENESS ANALYSIS OF THE DIABETES PREVENTION PROGRAM IN A SPANISH SETTING
COST-EFFECTIVENESS OF ACARBOSE FOR THE MANAGEMENT OF IMPAIRED GLUCOSE TOLERANCE IN SWEDEN
A PHARMACOECONOMIC ANALYSIS OF THE USE OF AN INTENSIVE STRATEGY FOR TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2 (DM T2)
CONTINGENT VALUATION OF AN INHALED DELIVERY SYSTEM FOR INSULIN
QUALITY OF LIFE IN SUBJECTS WITH AND WITHOUT TYPE-2 DIABETES MELLITUS
THE IMPACT OF VASCULAR EVENTS ON HEALTH-RELATED UTILITY IN PATIENTS WITH AND WITHOUT TYPE-2 DIABETES
A MULTIDIMENSIONAL HEALTH CARE INTERVENTION ASSESSMENT
VALIDATION OF ORAL ANTIDIABETIC DRUGS PRESCRIPTIONS
THERAPY CHANGE AND PROGRESSION TO INSULIN USE AMONG TYPE-2 DIABETIC PATIENTS NEWLY TREATED WITH SULFONYLUREA (SU) OR METFORMIN (MF) MONOTHERAPY
DRUG UTILIZATION OF GLITAZONES IN ITALY
COMPARISON OF BLOOD PRESSURE AND ATTRIBUTABLE HEALTHCARE COSTS BY DIHYDROPYRIDINE VS NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INITIATED FOR HYPERTENSION IN DIABETES MELLITUS PATIENTS,AND MONITORING OF RENAL PARAMETERS
LONG-TERM DIABETES COMPLICATIONS
EAGLE—DIABETES MODEL
ASSOCIATION BETWEEN DIMINISHED ACTIVITY OF DAILY LIVING AND VISUAL IMPAIRMENT IN SUBJECTS LIVING IN THE COMMUNITY
ASSOCIATION BETWEEN MORTALITY AND VISUAL IMPAIRMENT ESTIMATED FROM A FRENCH NATIONAL SURVEY
ANALYSIS OF CLINICAL EFFICACY OF LATANOPROST VS. THE MOST FREQUENT TREATMENT PATTERN FOR PRIMARY OPEN ANGLE GLAUCOMA (POAG) AND OCULAR HYPERTENSION (OH) IN POLAND
EFFECT OF CIRCADIAN INTRA-OCULAR PRESSURE VARIATIONS ON THERAPEUTIC DECISION MAKING
A COST-EFFECTIVENESS ANALYSIS OF LATANOPROST IN THE TREATMENT OF OPEN ANGLE GLAUCOMA IN SPAIN
COST EFFECTIVENESS OF LATANOPROST IN FIRST LINE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN THE UK
A PHARMACOECONOMIC ANALYSIS OF THE FIXED COMBINATION LATANOPROST/TIMOLOL VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF PATIENTS WITH GLAUCOMA IN SPAIN
RESOURCE UTILIZATION OF END-STAGE GLAUCOMA PATIENTS RECEIVING LOW VISION CARE
PREVALENCE OF FRACTURES AND DEPRESSION AND THEIR ASSOCIATION WITH BLINDNESS IN A MEDICARE POPULATION WITH PRIMARY OPEN-ANGLE GLAUCOMA
A NATION-WIDE ESTIMATE OF NON-MEDICAL SOCIO-ECONOMIC CONSEQUENCES ATTRIBUTABLE TO VISUAL IMPAIRMENT IN FRANCE
ESTIMATION OF NATIONWIDE COSTS OF ANNUAL ASSISTANCE ATTRIBUTABLE TO VISUAL IMPAIRMENT, FROM AN ACTIVITY OF DAILY LIVING QUESTIONNAIRE
NON-MEDICAL COSTS RELATED TO VISUAL IMPAIRMENT IN FOUR EUROPEAN COUNTRIES (FRANCE, GERMANY, ITALY AND THE UNITED KINGDOM)
A COST MINIMISATION ANALYSIS OF CUSTOM PAK® FOR CATARACT SURGERY
ANALYSIS OF RUSSIAN PHARMACEUTICAL MARKET OF ANTI-GLAUCOMA MEDICINES IN THE PERIOD 2000–2003
RESPONSIVENESS OF SELF-REPORTED VISUAL FUNCTIONING IN AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS TO GENERAL HEALTH AND CHANGES IN VISUAL ACUITY IN A PHASE I/II RANDOMIZED CONTROLLED TRIAL OF LUCENTIS™ (RANIBIZUMAB; RHUFAB V2)
IMPACT OF ATOPIC DERMATITIS ON PARENTΨS QUALITY OF LIFE AND USE OF DIRECT RESOURCES IN PATIENTS BETWEEN 2 AND 12 YEARS OLD. DAES STUDY
SCALING PROPERTIES OF THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)
LIVING WITH A DERMATOSIS
INTERPRETATION OF SCORES ON THE PSORIASIS INDEX OF QOL (PSORIQOL)
SENSITIVE SKIN
SUNBURNS AND QUALITY OF LIFE
HAIR LOSS, QUALITY OF LIFE IMPACT
HAIR LOSS, EPIDEMIOLOGICAL APPROACH
SUN SENSITIVITY AND PERSONAL BEHAVIOURS
IMPACTED CERUMEN
ASSOCIATION BETWEEN VITAMIN SUPPLEMENTS USAGE AND PRESENCE OF AGE-RELATED MACULAR DEGENERATION IN A LATINO POPULATION ADJUSTING FOR SELECTION BIAS USING PROPENSITY SCORES
ECONOMIC EVALUATION OF ON-DEMAND MAINTENANCE THERAPY WITH PROTON PUMP INHIBITORS IN PATIENTS WITH SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE—A MONTE-CARLO ANALYSIS FOR ITALY
THE ECONOMIC EVALUATION OF A RANDOMIZED TRIAL COMPARING “TEST-AND-TREAT” WITH PROMPT ENDOSCOPY IN PRIMARY CARE; THE HEALTH ECONOMICS OF THE SENSE-STUDY
COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE AND GENERIC OMEPRAZOLE IN ENDOSCOPY POSITIVE GERD PATIENTS IN GERMANY
USE OF CAPSULE ENDOSCOPY IN DIAGNOSING OBSCURE GASTROINTESTINAL BLEEDING
COSTS BENEFITS WITH ESOMEPRAZOLE 20 MG “ONDEMAND” TREATMENT IN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN BELGIUM
ECONOMIC EVALUATION OF RABEPRAZOLE VS. OMEPRAZOLE IN THE CURATIVE TREATMENT OF REFLUX OESOPHAGITIS
COST BENEFIT ANALYSIS OF TWO TREATMENTS FOR PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS
PHARMACOECONOMIC ASPECTS OF CROHŃS DISEASE IN SLOVAKIA
IS HELICOBACTER PYLORI “TEST AND TREAT” A COSTEFFECTIVE MANAGEMENT APPROACH FOR PATIENTS WITH TYPICAL REFLUX SYMPTOMS IN A POPULATION WITH A HIGH PREVALENCE OF H. PYLORI INFECTION
HEALTH RELATED QUALITY OF LIFE AMONG POLISH GASTROESOPHAGEAL REFLUX DISEASE PATIENTS
PSYCHOMETRIC VALIDATION OF TWO GASTROINTESTINAL (GI)-SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN RENAL TRANSPLANT PATIENTS WITH AND WITHOUT GI COMPLICATIONS
HEALTH-RELATED QUALITY OF LIFE AND PATIENT SELFPERCEIVED HEALTH STATUS IN IBS
EFFECT OF TEGASEROD IN WOMEN WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN SOUTH AFRICA
COST-EFFECTIVENESS EVALUATION FOR A NEW DIAGNOSTIC TEST CONSIDERING ALSO COSTS FOR FALSE NEGATIVE AND FALSE POSITIVE DIAGNOSES AT VARIOUS PREVALENCE RATES
CLINICAL PRACTICE GUIDELINE EVALUATION
COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN SUSPECTED METHICILLIN–RESISTANT STAPHYLOCOCCUS AUREUS IN NOSOCOMIAL PNEUMONIA IN GERMANY
LINEZOLID FOR THE TREATMENT OF SKIN AND SOFT-TISSUE MRSA INFECTIONS—A COST-EFFECTIVE ALTERNATIVE TO VANCOMYCIN
COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF VENTILATORASSOCIATED PNEUMONIA IN SPAIN
MEASURING RESOURCE USE AND DIRECT COSTS IN PATIENTS WITH HEPATITIS C VIRUS MANAGED IN A GASTROENTEROLOGY AND HEPATOLOGY SERVICE
CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIVIRAL COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS C ADMINISTERED ACCORDING TO THE NEW GENOTYPESPECIFIC GUIDELINES
COST MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VS. INTRAVENOUS AND ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS
ECONOMIC EVALUATION OF HIV TREATMENTS
COMPARING COSTS AND EFFECTIVENESS OF HAART TIMING IN HIV INFECTION
COST-EFFECTIVENESS OF EXPANDED HIV SCREENING OF BLOOD DONATIONS IN GHANA
PHARMACOECONOMIC EVALUATION OF HERD PROTECTION FOR THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWITZERLAND
COST-EFFECTIVENESS OF UNIVERSAL PNEUMOCOCCAL VACCINATION FOR INFANTS IN ITALY
ECONOMIC EVALUATION OF VORICONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN GERMANY
CALCULATING THE COST OF WOUND CARE IN A COMMUNITY SETTING IN THE UK
ACUTE ROTAVIRUS GASTROENTERITIS
ECONOMIC BURDEN AND FACTORS INFLUENCING COSTS IN GERMAN PATIENTS HOSPITALISED FOR COMMUNITYACQUIRED PNEUMONIA (CAP)
THE COSTS OF SEVERE SEPSIS MANAGEMENT IN INTENSIVE CARE UNITS IN POLAND
ASSESSING THE COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE SEPSIS IN POLAND
A COMPARISON OF COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS FIRST TREATMENT OF CHRONIC HEPATITIS C IN THE UK
COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND CASPOFUNGIN FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN
COST-BENEFIT ANALYSIS OF ANTI-INFLUENZA VACCINATION IN A PUBLIC HEALTH CARE UNIT
MODELLING THE COST-EFFECTIVENESS OF ACTIVATED PROTEIN C (XIGRIS®) TREATMENT OF SEPTIC PATIENTS IN INTENSIVE CARE UNITS IN HUNGARY
PROSPECTIVE STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTION IN CHILDREN YOUNGER THAN 3 YEARS IN GERMANY (PRI.DE)—ECONOMIC IMPACT OF COMMUNITY-ACQUIRED CASES TREATED BY OFFICE-BASED PEDIATRICIANS (PRIMARY CARE)
THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING SURGERY FOR COLORECTAL CANCER
IMPROVEMENT IN PATIENT-REPORTED DEPRESSION IN HIV+ PATIENTS EXPERIENCING GRADE 2 SIDE EFFECTS AFTER SUBSTITUTION OF THEIR PROTEASE INHIBITOR (PI)/NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH LOPINAVIR/RITONAVIR (LPV/R)
ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE MEASURES IN HIV AND AIDS
VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
WILLINGNESS TO PAY FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (TB) IN RURAL NEPAL
ASSESSMENT OF BODY CHANGES AND DISTRESS (ABCD) LIPODYSTROPHY QUESTIONNAIRE
ECONOMIC EVALUATION OF MENINGOCOCCAL C VACCINATION PROGRAMMES AND ITS IMPACT ON DECISION MAKING
FREQUENCY OF POTENTIAL DRUG-DRUG INTERACTIONS WITH TRIAZOLE ANTIFUNGAL USE IN DUTCH HOSPITAL SETTINGS
COSTS AND EFFECTS OF CHLAMYDIAL SCREENING PROGRAMS
BOOTSTRAP CONFIDENCE INTERVALS FOR THE ANGULAR TRANSFORMED ICER
A FRAMEWORK FOR HANDLING UNCERTAINTY AND VARIABILITY IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMS
ECONOMIC EVALUATION IN LATIN AMERICA
PMC3
CAN ECONOMIC EVALUATIONS BE MADE MORE TRANSFERABLE?
ARE THE BEST AVAILABLE, MOST APPLICABLE CLINICAL EFFECTIVENESS DATA USED IN ECONOMIC EVALUATIONS OF DRUG THERAPIES?
THE IMPORTANCE OF ACCOUNTING FOR THE PORTFOLIO EFFECTS IN COST EFFECTIVENESS ANALYSES
PMC7
PMC7
PMC8
PMC8
HEALTH PROGRAM IMPACT EVALUATION USING OBSERVED AND EXPECTED TIME SERIES OF PHARMACEUTICAL CONSUMPTIONS
ASP PLUS SIX PERCENT IN 2005-A CONCEPTUAL VIEW OF FUTURE PHYSICIAN PAYMENTS FOR DRUGS AND THEIR ADMINISTRATION IN THE OFFICE SETTING
COMPARING DIFFERENT APPROXIMATION METHODS FOR REMAINING LIFE EXPECTANCY IN DECISION TREES
EVALUATING DRUG SAFETY USING STOCHASTIC SIMULATION MODELS
DEVELOPING THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATIONS DATABASES (EURONHEED)
PERSONAL DRUG UTILIZATION REPORT (PDUR)—A CONTRIBUTION TO COST REDUCTION AND PATIENT EMPOWERMENT
WEIGHING DIAGNOSES IN EVALUATION STUDIES WITH AN APPLICATION TO SYNCOPE
VISUAL ANALOGUE SCALES
THERE'S NO F IN UTILITY
STATISTICAL ISSUES IN DISCRETE CHOICE MODELLING
CHRONIC DISEASE SCORES AMONG SENIORS IN ALBERTA, CANADA
DEVELOPMENT OF A NUTRITION RELATED QUALITY OF LIFE SCALE IN CHILDREN
AN EXPLORATION OF THE DISCREPANCIES BETWEEN HEALTH STATE VALUATIONS OF PATIENTS AND THE GENERAL POPULATION
REVIEW OF INSTRUMENTS MEASURING TREATMENT SATISFACTION WITH MEDICATION
REVIEW AND ASSESSMENT OF THE ECONOMIC EVALUATION STUDIES ON HEALTH CARE IN MEXICO
IMPACT OF WEIGHT GAIN ON TREATMENT EFFECTIVENESS WITH OLANZAPINE OR ARIPIPRAZOLE, CONSIDERING NONADHERENCE, RELAPSE AND COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN FINLAND
GEO OBSERVATIONAL STUDY
FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED ON RISPERIDONE OR OLANZAPINE
THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER IN AUSTRALIA; A RETROSPECTIVE AUDIT
FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED FROM PSYCHIATRIC HOSPITALS IN THE UK ON RISPERIDONE OR OLANZAPINE
HEALTH EFFECTS AND HEALTH CARE RESOURCE UTILIZATION IN POLISH SCHIZOPHRENIC OUTPATIENTS INITIATING OR CHANGING TO OLANZAPINE OR TYPICAL ANTIPSYCHOTIC MONOTHERAPY
THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR
COSTS AND EFFECTS OF RISPERDAL CONSTA (TM) IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN PORTUGAL
A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE UNITED KINGDOM
ECONOMIC ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN NEW ZEALAND
PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN THE UNITED KINGDOM
THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDER IN THE UK
THE COST-EFFECTIVENESS OF PAROXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER IN JAPAN
THE HEATLH—RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY
ANNUAL SOCIETAL COSTS AND QUALITY OF LIFE IN CHILDREN WITH NEUROPSYCHIATRIC DISORDERS IN SWEDEN
TOTAL HEALTH CARE CONSUMPTION AND COSTS OF SICKNESS FUND INSURED PATIENTS IN THE NETHERLANDS
COST-UTILITY ANALYSIS OF MEDICAL CO-PRESCRIPTION OF HEROIN COMPARED WITH METHADONE MAINTENANCE TREATMENT FOR CHRONIC,TREATMENT RESISTANT HEROIN ADDICTS
ASSESSING THE TOTAL COST OF CARE FOR CEREBRAL PALSY PATIENTS WHO USE BOTULINUM TOXIN TYPE A
COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN SETTING OF RISPERIDONE LONG-ACTING INJECTION FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA WHO ARE PARTIALLY ADHERENT TO THEIR MEDICATION
THE PERCEIVED BENEFITS OF DOSING SCHEDULES FOR CHILDREN WITH ADHD
PATIENT-REPORTED OUTCOMES
IS HEALTH-RELATED QUALITY OF LIFE EVALUATION DIFFERENT BETWEEN CLINICAL TRIALS AND OBSERVATIONAL STUDIES IN MAJOR DEPRESSIVE DISORDER?
INCIDENCE, PREVALENCE AND TREATMENT PATTERNS OF PATIENTS WITH ADHD SYMPTOMS IN THE NETHERLANDS
ADHD TREATMENT AND CO-MORBIDITIES
EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA
EMERGENCY DEPARTMENTS
SSRI UTILIZATION AND PERSISTENCE IN A CALIFORNIA MEDICAID POPULATION
THE EFFECT OF RAISING THREE TIER CO-PAYMENTS ON SSRI ANTIDEPRESSANT COMPLIANCE RATES
METABOLIC OUTCOMES OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
ECONOMIC EVALUATION OF THE ADMINISTRATION OF FOLLITROPIN-Â WITH A PEN DEVICE COMPARED WITH ADMINISTRATION OF MENOTROPIN BY CONVENTIONAL SYRINGE
HOW MUCH DOES UNINTENDED PREGNANCY COST THE UK HEALTH CARE SYSTEM?
IMPROVING THE DELIVERY OF CHILD AND MATERNAL HEALTH CARE IN A POOR SETTING
VALIDATION OF THE SPANISH VERSION OF THE SELF-ESTEEM AND RELATIONSHIP (SEAR) QUESTIONNAIRE FOR MEN WITH ERECTILE DYSFUNCTION (ED)
INFERTILITY TREATMENT POLICIES IN GERMANY AND THE UNITED KINGDOM—WILLINGNESS TO PAY AMONG AFFECTED COUPLES
SHORT-TERM AND LONG-TERM PSYCHOSOCIAL CONSEQUENCES OF FALSE POSITIVE SCREENING MAMMOGRAPHY—DEVELOPMENT OF TWO NEW QUESTIONNAIRE BASED ON THE PSYCHOLOGICAL CONSEQUENCES QUESTIONNAIRE (THE PCQ)
PREVALENCE, HEALTH RESOURCES USAGE AND COST OF VASCULAR DEMENTIA IN COMPARISON WITH ALZHEIMER DISEASE IN A POPULATION SETTING IN SPAIN
STROKE SEVERITY AND EARLY OUTCOMES AFTER FIRSTEVER ISCHEMIC STROKE
PREDICTORS FOR DIRECT AND INDIRECT COSTS IN PARKINSON'S DISEASE
NEW LEVODOPA/CARBIDOPA/ENTACAPONE (STALEVO®) RESULTS IN BETTER QUALITY OF LIFE FOR PARKINSON'S DISEASE PATIENTS AND SAVES COSTS TO THE SOCIETY
SOCIAL COSTS OF PARKINSON DISEASE IN ITALY
THE HOSPITAL COSTS OF PRIMARY STROKE PATIENTS MANAGEMENT IN POLAND
COSTS OF STROKE UNIT CARE IN GERMANY
COST-EFFECTIVENESS OF THROMBOLYSIS WITH RT-PA FOR ACUTE ISCHEMIC STROKE IN TAIWAN
INDIRECT COSTS ASSOCIATED TO INSOMNIA IN OCCUPATIONAL HEALTH
THE SOCIOECONOMIC IMPACT OF NARCOLEPSY
EFFECT OF COMORBIDITIES ON MEDICAL CARE USE AND COST AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER
HEALTHCARE UTILIZATION AND SOCIOECONOMIC ASPECTS OF NEUROMUSCULAR DISEASES
PROFILE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE
THE COST-EFFECTIVENESS OF TREATING PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) USING ROPINIROLE
RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORTÒ AND BOTOXÒ IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM—THE REAL DOSE STUDY EXPANSION—COST CONSIDERATIONS BASED ON DRUG START
A COMPARATIVE STUDY ON RESOURCE USE, COSTS AND CAREGIVER BURDEN BETWEEN RASAGILINE AND ENTACAPONE IN FLUCTUATING PARKINSON'S DISEASE (PD) PATIENTS
MARKOV MODEL OF ADJUNCTIVE ANTIEPILEPTIC TREATMENT FOR CHILDREN—A COMPARISON OF TOPIRAMATE AND LAMOTRIGINE
COSTS AND OUTCOMES ASSOCIATED WITH THE USE OF BOTULINUM TOXIN TYPE A (BTX-A) IN THE TREATMENT OF FLEXED WRIST/CLENCHED FIST POST-STROKE SPASTICITY
HEALTHCARE RESOURCES USED BY SPANISH PRIMARY CARE PHYSICIANS IN PATIENTS WITH SUBJECTIVE MEMORY COMPLAINTS OR COGNITIVE IMPAIRMENT.THE ISSEA STUDY
VALIDATING THE RESTLESS LEGS SYNDROME QUALITY OF LIFE QUESTIONNAIRE (RLSQOL) IN A TRIAL PATIENT POPULATION
A SIMPLIFIED SEVERITY SCALE FOR THE ASSESSMENT OF RESTLESS LEGS SYNDROME
INDEPENDENT EFFECT OF DYSKINESIA ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE—A MULTIVARIATE ANALYSIS
EFFECT OF DISEASE-SPECIFIC COMPLICATIONS ON THE PREDICTION OF UTILITIES IN PARKINSON'S DISEASE
CHRONIC NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT QUALITY OF LIFE AND DISABILITY
NEUROPATHIC PAIN (NEP) IMPACT ON PATIENT MENTAL FUNCTIONING, SYMPTOM LEVELS OF ANXIETY AND DEPRESSION,AND SLEEP DISTURBANCE
COMPARING CLASSIFICATION AND REGRESSION TREE ANALYSIS WITH MULTIPLE REGRESSION FOR TRANSLATING A CLINICAL PARKINSON'S DISEASE SCALE INTO UTILITIES
INTERNAL, EXTERNAL,AND CROSS-MODEL VALIDATION OF A MULTI-OUTCOME DECISION MODEL FOR PARKINSON'S DISEASE
A NEW SCREENING TOOL FOR MIGRAINE IN THE GENERAL POPULATION
MAPPING THE INTERNATIONAL RESTLESS LEGS SYNDROME RATING SCALE (IRLS) TO THE EQ-5D BY FOUR CLINICIANS
CENTERED REGRESSION FUNCTIONS AS A TECHNIQUE TO IMPROVE FLEXIBILITY AND TRANSFERABILITY OF MARKOV MODELS
ESTIMATING THE COST OF ILLNESS IN EUROPE—A MODEL WITH MULTIPLE SCLEROSIS AS AN EXAMPLE
COST-OF-ILLNESS STUDY IN ACROMEGALIC PATIENTS IN ITALY
THE DEFICIT IN HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR GROWTH HORMONE DEFICIENT (GHD) PATIENTS IN SPAIN AND ENGLAND & WALES
THE COST-EFFECTIVENESS OF EXTENDED RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN GERMANY AND THE UNITED KINGDOM
COST-EFFECTIVENESS ANALYSIS OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-RELEASE TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE BLADDER IN SPAIN
ECONOMIC ASSESSMENT OF URO-VAXOM® IN FEMALE PATIENTS WITH RECURRENT URINARY TRACT INFECTION IN GERMANY
PATIENT PERCEPTION OF OAB DRUG THERAPY SUCCESS IS ASSOCIATED WITH LESS HEALTHCARE RESOURCE USE
ECONOMIC VALUATION OF THE EFFECTS OF DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF CHRONIC RENAL DISEASE
COST OF RENAL TRANSPLANTATION IN BELGIUM
WHEN SHOULD ERYTHROPOIETIN (EPO) BE REPLACED BY PACKED RED BLOOD CELL TRANSFUSION (TR) IN HEMODIALYSIS (HD) PATIENTS?
2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL
EVALUATION OF THE COST UTILITY OF SIROLIMUS VERSUS TACROLIMUS FOR IMMUNOSUPPRESSION FOR RENAL TRANSPLANTATION IN THE UNITED KINGDOM
A HEALTH ECONOMIC EVALUATION OF 6 MONTHS ALFUZOSIN TREATMENT IN THE MANAGEMENT OF ACUTE URINARY RETENTION
COST-CONSEQUENCES OF TREATING WOMEN WITH STRESS URINARY INCONTINENCE WITH DULOXETINE FROM THE PERSPECTIVE OF THE STATUTORY HEALTH INSURANCE IN GERMANY
LONG-TERM COST-EFFECTIVENESS MODELLING OF FEEDBACK MICROWAVE THERMOTHERAPY VERSUS DRUG TREATMENT IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS
LOWER MENTAL HEALTH SCORES MEASURED USING THE SF-36 HEALTH SURVEY IS AN INDEPENDENT PREDICTOR OF MORTALITY IN YOUNGER PATIENTS RENAL REPLACEMENT THERAPY
ELDERLY PATIENTS STARTING RENAL REPLACEMENT THERAPY (RRT) HAVE LOWER LOSS OF HEALTH RELATED QUALITY OF LIFE (HRQL) THAN YOUNGER ONES DURING THE FIRST TWO YEARS
PATIENTS UNDERGOING PERITONEAL DIÁLISIS HAVE BETTER PERCEIVED HEALTH IN SEVERAL SPECIFIC PROBLEMS RELATED WITH RENAL DISEASE THAN PATIENTS UNDERGOING HEMODIALYSIS
VALIDATION OF TWO QUESTIONNAIRES ON SYMPTOMS AND QUALITY OF LIFE IN ITALIAN WOMEN WITH LUTS
EVALUATION OF TREATMENT OF FEMALE URINARY INCONTINENCE WITH THE ICIQ-UI SF QUESTIONNAIRE
VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE ACTIVITY IMPAIRMENT AS A RESULT OF UNCOMPLICATED URINARY TRACT INFECTION
DEVELOPMENT OF A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTRES
PREVALENCE AND QUALITY OF LIFE IN FRENCH WOMEN WITH STRESS URINARY INCONTINENCE
IMPLICATIONS OF OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A MANAGED CARE POPULATION
AN ANALYSIS OF PATIENTS ON WAITING LISTS TO RECEIVE SURGERY FOR STRESS URINARY INCONTINENCE (SUI) IN ENGLAND AND SCOTLAND
DERIVING UNIT COSTS FOR RESOURCE UTILISATION IN PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE)—AN OBSERVATIONAL STUDY IN 14 EUROPEAN COUNTRIES
LANTHANUM CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATAEMIA